Tech Company Financing Transactions

Azelon Pharmaceuticals Funding Round

On 10/5/2004, Azelon Pharmaceuticals received $7 million in Series A funding from Seaflower Ventures and Vengrowth Asset Management.

Transaction Overview

Announced On
Transaction Type
Venture Equity
Series A
Proceeds Purpose
The proceeds from the final tranche of our Series A provide us with the resources to rapidly move Ostabolin-C(TM) into a dose-ranging Phase II clinical trial with a four month treatment duration in approximately 200 patients in early 2005

Company Information

Company Status
Out of Business
Mailing Address
200 Barr Harbor Dr. 400
West Conshohocken, PA 19428
Email Address
The lead program for the Company, a next-generation PTH analogue (Ostabolin-C(TM) s.c. injection) for the treatment of osteoporosis, recently began a Phase II clinical trial. Approximately 250 patients will receive daily injections of one of four doses of Ostabolin-C(TM) or placebo for four months in 25 centers located in the US and Canada.
Azelon Pharmaceuticals LinkedIn Company Profile
Social Media
Azelon Pharmaceuticals Company Twitter Account
Company News
Azelon Pharmaceuticals News
Azelon Pharmaceuticals on Facebook
Azelon Pharmaceuticals on YouTube

Management Team

Email & Social
Chief Executive Officer
Joan Lau
  Joan Lau LinkedIn Profile  Joan Lau Twitter Account  Joan Lau News  Joan Lau on Facebook



Browse more venture capital transactions:

Prev: 10/5/2004: True Commerce venture capital transaction
Next: 10/5/2004: Blacksmith Applications venture capital transaction


Share this article


Where The Data Comes From

We do our best to document every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with, an affiliated venture.


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities


Business Glossary